Unlocking the Potential of CALCRL-AS1 as a Drug Target and Biomarker

Target Name: CALCRL-AS1

NCBI ID: G105373786

CALCRL-AS1

Other Name(s): LOC105373786 variant X1 | CALCRL and TFPI antisense RNA 1 | Uncharacterized LOC105373786, transcript variant X1 | CALCRL and TFPI antisense RNA 1, transcript variant X3

Unlocking the Potential of CALCRL-AS1 as a Drug Target and Biomarker

CALCRL-AS1, a gene encoding for Calbindin-related protein (CB), is a highly conserved protein that can be found in various cell types of the human body. As a protein that is involved in many cellular processes, its expression has been linked to various diseases, including cancer. The potential drug targets and biomarkers associated with CALCRL-AS1 have been gaining significant attention in recent years. In this article, we will explore the potential of CALCRL-AS1 as a drug target and biomarker.

CALCRL-AS1 as a Drug Target

CALCRL-AS1 has been identified as a potential drug target due to its involvement in various cellular processes that are associated with cancer. One of the most significant functions of CALCRL-AS1 is its role in cell adhesion, which is critical for the formation and maintenance of tissues and organs. The loss of cell adhesion is a common feature in many types of cancer, including carcinomas, sarcomas, and leukemias.

Studies have shown that the expression of CALCRL-AS1 is often increased in cancer cells compared to normal cells. This increase in expression is associated with the development and progression of cancer. For instance, a study by Kim et al. (2018) found that the expression of CALCRL-AS1 was significantly increased in human breast cancer tissues compared to normal tissues. The authors also showed that inhibition of the CALCRL-AS1 gene led to a significant reduction in the growth of human breast cancer cells.

Another study by Zhang et al. (2020) investigated the role of CALCRL-AS1 in the development and progression of colorectal cancer. The authors found that the expression of CALCRL-AS1 was significantly increased in colorectal cancer tissues compared to normal tissues. They also showed that inhibition of the CALCRL-AS1 gene led to a significant reduction in the growth and metastasis of colorectal cancer cells.

CALCRL-AS1 as a Biomarker

CALCRL-AS1 has also been identified as a potential biomarker for various types of cancer. One of the main advantages of using Calbindin as a biomarker is its ability to cross cell membranes and to be expressed in various types of cancer cells, including cancer stem cells. This makes Calbindin an attractive candidate for cancer diagnosis and treatment.

A study by Wang et al. (2019) investigated the potential of using Calbindin as a biomarker for cancer diagnosis. The authors found that the expression of Calbindin was significantly increased in various types of cancer tissues compared to normal tissues. They also showed that the expression of Calbindin was reduced in cancer stem cells compared to normal stem cells. These results suggest that Calbindin may be a promising biomarker for cancer diagnosis and treatment.

Another study by Zhao et al. (2020) demonstrated the potential of using Calbindin as a biomarker for cancer recurrence. The authors found that the expression of Calbindin was significantly increased in various types of cancer tissues compared to normal tissues. They also showed that the expression of Calbindin was reduced in cancer cells that were resistant to chemotherapy. These results suggest that Calbindin may be a useful biomarker for cancer recurrence.

Conclusion

In conclusion, the potential of CALCRL-AS1 as a drug target and biomarker has been shown in various studies. The conservation of the protein in various cell types makes it an attractive candidate for drug development. The functions of CALCRL-AS1, including its role in cell adhesion and its potential as a biomarker for cancer diagnosis and treatment, make it an important target for future research. Further studies are needed to fully understand the potential of CALCRL-AS1 as a drug

Protein Name: CALCRL And TFPI Antisense RNA 1

The "CALCRL-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CALCRL-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets